This study will compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD.

Each patient received a sham injection in one eye and active treatment in the other eye. The eye receiving active treatment was selected based on a randomization schedule.

Inclusion Criteria:

• Clinical diagnosis bilateral GA secondary to AMD of ≥ 0.5 and ≤ 7 MPS disc areas
• Males and non-pregnant females 55 years old or older

Exclusion Criteria:

• GA secondary to any condition other than AMD in either eye
• History of or current CNV in either eye or the need for anti-angiogenic therapy
• Glaucoma or ocular hypertension (IOP > 21 mmHg OR concurrent therapy at screening with IOP-lowering agents) in either eye
• Treatment with intravitreal, subtenon, or periocular steroid within 6 months prior to enrollment in either eye
• Any change in systemic steroid therapy within 3 months of screening
• History of vitrectomy in either eye
• Any ocular surgery within 12 weeks of screening in either eye

Patients received either the 0.2µ/day or 0.5µ /day dose as well as a sham injection in the fellow eye. The total number of subjects enrolled/analyzed was 17.

Each patient received a sham injection in one eye and active treatment in the other eye.